Development of Meloxicam-Human Serum Albumin Nanoparticles for Nose-to-Brain Delivery via Application of a Quality by Design Approach

• Prif Awduron: Gábor Katona (Awdur), György Tibor Balogh (Awdur), Gergő Dargó (Awdur), Róbert Gáspár (Awdur), Árpád Márki (Awdur), Eszter Ducza (Awdur), Anita Sztojkov-Ivanov (Awdur), Ferenc Tömösi (Awdur), Gábor Kecskeméti (Awdur), Tamás Janáky (Awdur), Tamás Kiss (Awdur), Rita Ambrus (Awdur), Edina Pallagi (Awdur), Piroska Szabó-Révész (Awdur), Ildikó Csóka (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: MDPI AG, 2020-01-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

The aim of this study was to optimize the formulation of meloxicam (MEL)-containing human serum albumin (HSA) nanoparticles for nose-to-brain via a quality by design (QbD) approach. Liquid and dried formulations of nanoparticles containing Tween 80 and without the surfactant were investigated. Vario...